Technical Perspectives on Agenus, Coherus Biosciences, Global Blood Therapeutics, and Intercept Pharma

Friday, January 5, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Jan. 5, 2018 /PRNewswire/ -- strives to bring the best free research to the investment

community.  Today we are offering reports on AGEN, CHRS, GBT, and ICPT which can be accessed for free by signing up to Today's focus has been shifted on the Biotech industry, which broadly segments into the Medical
and Agricultural markets. Although Enterprising Biotechnology is also being applied to other exciting areas like industrial production of chemicals and bioremediation, the use in these areas is still specialized and limited. Pre-market this morning, observes the previous performance of Agenus Inc. (NASDAQ: AGEN), Coherus Biosciences Inc. (NASDAQ: CHRS), Global Blood Therapeutics Inc. (NASDAQ: GBT), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). All you have to do is sign up today for this free limited time offer by clicking the link below.


Shares in Lexington, Massachusetts headquartered Agenus Inc. saw a slight drop of 0.56%, ending Thursday's trading session at $3.52. The stock recorded a trading volume of 721,834 shares. The Company's shares have gained 3.83% since the last one week. The stock is trading 3.50% below its 50-day moving average. Moreover, shares of Agenus, which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer, have a Relative Strength Index (RSI) of 47.84.  

On January 03rd, 2018, Agenus announced new leadership appointments: Dr. Hagop Youssoufian, MD was named Senior Clinical Strategist; Dr. John Castle, Ph.D., was appointed as Head of Translational Medicine and Bioinformatics; and Dr. Tyler Curiel, MD, MPH was appointed Senior Strategist for Translational and Biomarker Development. These new appointments have been made to enhance the Company's team, and advance combination clinical programs, which will support its planned BLA filings in the second half of 2019 and in 2020. Get the full research report on AGEN for free by clicking below at:

Coherus Biosciences

Redwood City, California headquartered Coherus Biosciences Inc.'s stock jumped 4.82%, closing the day at $11.95. A total volume of 1.90 million shares was traded, which was above their three months average volume of 557,030 shares. The Company's shares have surged 34.27% in the past month. The stock is trading 22.50% above its 50-day moving average. Additionally, shares of Coherus Biosciences, which focuses on developing and commercializing biosimilar products worldwide, have an RSI of 71.42. 

On January 02nd, 2018, Coherus Biosciences announced that senior management will present at the 36th annual J.P. Morgan healthcare conference on January 08th, 2017, at 2:00 p.m. PT in San Francisco. The audio portion of the presentation will be available on the Investors page of the Company website. Access the free research report on CHRS now by signing up at:

Global Blood Therapeutics

On Thursday, shares in South San Francisco, California headquartered Global Blood Therapeutics Inc. recorded a trading volume of 669,401 shares. The stock ended the day 1.06% lower at $41.90. The Company's shares have advanced 5.41% in the past month, 29.52% over the previous three months, and 164.35% over the past one year. The stock is trading above its 50-day and 200-day moving averages by 7.27% and 30.42%, respectively. Furthermore, shares of the Company, which engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders, have an RSI of 55.21.  

On December 14th, 2017, research firm Needham reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $51 a share to $70 a share.

On January 03rd, 2018, Global Blood Therapeutics announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on January 10th, 2018, at 7:30 a.m. PT. The live webcast of the presentation and Q&A session will be available under the Investors section of the Company's website. Are you already registered with Wall St. Equities? Do so now for free, and get the report on GBT at:

Intercept Pharmaceuticals

New York headquartered Intercept Pharmaceuticals Inc.'s stock declined 0.88%, finishing yesterday's session at $56.03 with a total trading volume of 854,496 shares. The Company's shares are trading below their 50-day moving average by 8.92%. Shares of the Company, which focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases, have an RSI of 34.04. Aspiring Member, please take a moment to register below for your free research report on ICPT at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Cision View original content:

SOURCE Wall St. Equities


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store